These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 24356717)
1. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Tazawa H; Kagawa S; Fujiwara T Acta Med Okayama; 2013; 67(6):333-42. PubMed ID: 24356717 [TBL] [Abstract][Full Text] [Related]
2. Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer. Tazawa H; Kuroda S; Hasei J; Kagawa S; Fujiwara T Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28698504 [TBL] [Abstract][Full Text] [Related]
3. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Tazawa H; Yano S; Yoshida R; Yamasaki Y; Sasaki T; Hashimoto Y; Kuroda S; Ouchi M; Onishi T; Uno F; Kagawa S; Urata Y; Fujiwara T Int J Cancer; 2012 Dec; 131(12):2939-50. PubMed ID: 22492316 [TBL] [Abstract][Full Text] [Related]
4. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model. Wang H; Wei F; Li H; Ji X; Li S; Chen X Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955 [TBL] [Abstract][Full Text] [Related]
5. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976 [TBL] [Abstract][Full Text] [Related]
6. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells. Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenoviruses for the treatment of brain tumors. Gomez-Manzano C; Fueyo J Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384 [TBL] [Abstract][Full Text] [Related]
10. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Klein SR; Piya S; Lu Z; Xia Y; Alonso MM; White EJ; Wei J; Gomez-Manzano C; Jiang H; Fueyo J Oncogene; 2015 Oct; 34(41):5295-301. PubMed ID: 25619840 [TBL] [Abstract][Full Text] [Related]
11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007 [TBL] [Abstract][Full Text] [Related]
12. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462 [TBL] [Abstract][Full Text] [Related]
13. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926 [TBL] [Abstract][Full Text] [Related]
14. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626 [TBL] [Abstract][Full Text] [Related]
15. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy. Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583 [TBL] [Abstract][Full Text] [Related]
16. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Kim J; Kim JH; Choi KJ; Kim PH; Yun CO Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410 [TBL] [Abstract][Full Text] [Related]
17. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment. Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091 [TBL] [Abstract][Full Text] [Related]
19. Crosstalk between oncolytic viruses and autophagy in cancer therapy. Jin KT; Tao XH; Fan YB; Wang SB Biomed Pharmacother; 2021 Feb; 134():110932. PubMed ID: 33370632 [TBL] [Abstract][Full Text] [Related]
20. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo. Gomez-Gutierrez JG; Nitz J; Sharma R; Wechman SL; Riedinger E; Martinez-Jaramillo E; Sam Zhou H; McMasters KM Virology; 2016 Jan; 487():249-59. PubMed ID: 26561948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]